姑息放疗对比同步化放疗联合姑息放疗在不可根治性放化疗的非小细胞肺癌患者中的随机III期试验:TROG 11.03
本研究比较了不可根治性放化疗、因胸腔内病变出现症状的III/IV期NSCLC患者接受PRT36/12或C-PRT40/20的胸腔内症状缓解率、生活质量和毒性。结果显示两种方案均有效缓解症状,但C-PRT40/20未提供更优的症状缓解,仅治疗期间生活质量更优。
要点
- PRT36/12与C-PRT40/20在6周时均显著降低胸腔内症状负担指数(P<.01)。
- 两治疗组间胸腔内症状缓解率无差异(P=.34)。
- C-PRT40/20治疗期间生活质量显著更优,但毒性无差异。
核心结论
- PRT36/12和C-PRT40/20均可有效缓解不可根治性放化疗的III期及IV期NSCLC患者的胸腔内症状。
- 在PRT40/20基础上加用化疗未带来更优的症状缓解。
研究设计与样本
- 纳入III或IV期NSCLC、ECOG PS 0-1、存在呼吸困难、咳嗽、咯血或胸痛中至少一项症状的患者。
主要发现
- 全队列6周时胸腔内症状负担指数较基线显著降低(调整后平均差异-8.77,标准误2.67;95%CI -13.97%至-3.58%;P<.01),组间无差异(P=.34)。
- 两种治疗均有效缓解各单项症状,组间无显著差异。
- 治疗期间C-PRT40/20组生活质量显著更优;基线至治疗后6周总体生活质量组间无差异。
- 治疗期间及基线至6周毒性组间无差异;无进展生存期无差异。
- 中位生存期C-PRT40/20组有3个月的非统计学显著改善。
关键数值与推荐
- PRT36/12方案:姑息放疗36Gy/12次。
- C-PRT40/20方案:同步化疗联合姑息放疗40Gy/20次。
临床怎么用
- 对于不适合根治性放化疗、ECOG PS 0-1、因胸腔内病变出现症状的III/IV期NSCLC患者,可考虑PRT36/12或C-PRT40/20进行姑息治疗。
- 加用化疗未显示更优症状缓解,决策时需权衡治疗期间生活质量获益与生存期非显著改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compared intrathoracic symptom response rate, quality of life (QOL) and toxicity in patients with non-small cell lung cancer (NSCLC) not suitable for radical chemo-radiation therapy, experiencing symptoms from intrathoracic disease, who were randomized to receive palliative radiation therapy (PRT36/12) or concurrent chemotherapy and PRT (C-PRT40/20). METHODS AND MATERIALS: We included patients with stage III or IV NSCLC, with a Eastern Cooperative Oncology Group Performance status 0 to 1, who were experiencing at least one of the following: dyspnea, cough, hemoptysis, or chest pain. The primary outcome was a change in intrathoracic response rate from baseline to 6 weeks post completion of therapy using (1) a composite measure, the Intrathoracic Symptom Burden Index(ISBI), and (2) individual symptom scores measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire - Lung Cancer 13 item (QLQ-LC 13) instruments. RESULTS: Seventy-six patients were recruited with 68 eligible for analysis. In addition, 42.6% and 57.4% had stage III and IV disease, respectively. The Intrathoracic Symptom Burden Index was significantly lower at 6 weeks posttreatment than at baseline (adjusted mean difference -8.77, standard error 2.67; 95% confidence interval, -13.97% to -3.58%; P < .01) for the entire cohort with no difference between trial arms (P = .34). Both treatments provided effective palliation of individual symptoms with no significant difference between trial arms. QOL during treatment was significantly better for patients receiving C-PRT(40/20). There was no difference between arms in overall QOL between baseline and 6 weeks posttreatment. There was no difference in toxicity between treatment arms during treatment nor between baseline and 6 weeks posttreatment. There was no difference in progression-free survival. A nonstatistically significant 3-month improvement in median survival favored C-PRT(40/20). CONCLUSION: PRT(36/12) and C-PRT(40/20) provide effective symptom palliation in patients with stage III NSCLC not suitable for radical chemo-radiation therapy and in patients with stage IV disease. Chemotherapy added to PRT(40/20) does not provide superior symptomatic relief in this patient cohort.
引用
- Lehman M, Bernard A, See A, et al. A Randomized Phase 3 Trial of Palliative Radiation Therapy Versus Concurrent Chemotherapy and Palliative Radiation Therapy in Patients With Good Performance Status, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer With Symptoms due to Intrathoracic Disease Who are Not Suitable for Radical Chemo-radiation Therapy: Results of the Trans-Tasman Radiation Oncology Group 11.03 Trial. Pract Radiat Oncol. 2020. PMID: 33271352. doi:10.1016/j.prro.2020.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。